Jvion is a healthcare technology company that develops software designed to predict and prevent patient-level disease and financial losses leading to increased waste.
Jvion, the Atlanta-based leader in clinical predictive algorithms, announced the release of a Clostridium Difficile (C Diff) predictive use case for inpatient and outpatient providers. The C Diff use case is the latest in a broad compliment of predictive capabilities that span hospital acquired infections, chronic conditions, and individual illnesses. Using the firm’s RevEgis patient phenotype platform, the C Diff solution flags at risk individuals to help support clinician decision-making and reduce the likelihood of the deadly infection. These predictions can be produced in both inpatient and outpatient settings and can be integrated directly into existing electronic health record management systems.
“C.diff is a serious and deadly problem,” said Todd Schlesinger, VP for Jvion. “With this use case, we’ve extended the award-winning predictive capabilities already delivered through RevEgis to address a very pressing and lethal challenge facing all healthcare settings.”
A new report from the Centers for Disease Control and Prevention (CDC) shows that C Diff infected nearly half a million Americans. Of those infected, 15,000 died as a result of the bacteria. Anyone taking an antibiotic is at risk of developing a C Diff infection, but older adults over 65 are particularly susceptible. According to the study, people taking antibiotics are 7 to 10 times more likely to get C Diff while on their prescription and in the subsequent 30 days after treatment. The bacteria are spread through unclean surfaces and dirty hands. A recent Ohio-based study found that six out of every seven outpatient settings test positive for C Diff.
Jvion, the leader in clinical predictive algorithms, announced the development of a Clostridium Difficile (C Diff) use case to help clinicians reduce the risk of deadly infections inside and outside the hospital.
Todd went on the say that, “our goal is to help clinicians reduce the occurrence of C Diff infections while also lowering mortality rates attributed to the bacteria. We designed our solution so that it fits seamlessly into the clinical workflow and provides the additional insights that help support physicians and reduce the risk of C Diff incidences.”
RevEgis has won numerous awards including: designation as Gartner Cool Vendor for Healthcare Providers; the 2014 Intel Innovation Award; top honors from Fierce Health IT in the “Data Analytics” category, and as an overall award of “Best in Show: Fiercest Cost-Saving Solution.” These awards recognize RevEgis’s impact on the reduction of various diseases and health concerns. To learn more about Jvion, their full suite of Big Data predictive analytic solutions, and how they can help clinicians reduce C Diff infections please visit http://www.jvion.com
Jvion is a healthcare technology company that develops software designed to predict and prevent patient-level disease and financial losses leading to increased waste. The company offers a suite of big-data enabled solutions that combine clinical intelligence with deep machine learning to help providers protect their revenues while improving patient health outcomes. Their objective is simple—stop the waste of resources and lives by predicting and stopping losses before they ever happen.
To read the article in its entirety click on the link below: